Tau-targeting therapies for Alzheimer disease: current status and future directions.
Ontology highlight
ABSTRACT: Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain, with associated loss of synapses and neurons, which eventually results in dementia. Many of the early attempts to develop treatments for AD focused on Aβ, but a lack of efficacy of these treatments in terms of slowing disease progression led to a change of strategy towards targeting of tau pathology. Given that tau shows a stronger correlation with symptom severity than does Aβ, targeting of tau is more likely to be efficacious once cognitive decline begins. Anti-tau therapies initially focused on post-translational modifications, inhibition of tau aggregation and stabilization of microtubules. However,
SUBMITTER: Congdon EE
PROVIDER: S-EPMC10965012 | biostudies-literature | 2023 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA